Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma

BACKGROUND: Cabozantinib inhibits tyrosine kinases, including vascular endothelial growth factor receptors 1, 2, and 3, MET, and AXL, which are implicated in the progression of hepatocellular carcinoma and the development of resistance to sorafenib, the standard initial treatment for advanced diseas...

全面介紹

Na minha lista:
書目詳細資料
發表在:N Engl J Med
Main Authors: Abou-Alfa, G.K., Meyer, T., Cheng, A.-L., El-Khoueiry, A.B., Rimassa, L., Ryoo, B.-Y., Cicin, I., Merle, P., Chen, Y.H., Park, J.-W., Blanc, J.-F., Bolondi, L., Klümpen, H.-J., Chan, S.L., Zagonel, V., Pressiani, T., Ryu, M.-H., Venook, A.P., Hessel, C., Borgman-Hagey, A.E., Schwab, G., Kelley, R.K.
格式: Artigo
語言:Inglês
出版: 2018
主題:
Article
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC7523244/
https://ncbi.nlm.nih.gov/pubmed/29972759
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa1717002
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍